Jazz Pharmaceuticals PLC (JAZZ.OQ) Key Developments | Reuters.com
Edition:
United States

Analyst Research

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Jazz Pharmaceuticals PLC raises FY 2014 revenue guidance; reaffirms FY 2014 EPS guidance


Tuesday, 5 Aug 2014 04:05pm EDT 

Jazz Pharmaceuticals PLC:Expect FY 2014 revenues of $1.125-$1.165 bln (prior range of $1.100-$1.160 bln).FY 2014 GAAP net income per diluted share of $0.47-$0.90.FY 2014 Non-GAAP Adjusted Net Income Per Diluted Share of $8.00-$8.25.FY 2014 revenue of $1.132 bln and EPS of $8.07 - Thomson Reuters I/B/E/S.